IMA401-101 – Treatment of patients with solid tumors with IMA401 TCER®, a bispecific T-cell receptor (Phase I trial); alone or in combination with checkpoint inhibitor

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506854-19-00

Acronym

IMA401-101

Enrollment

Registered

2023-09-28

Start date

2022-05-19

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026